2 news items
Adaptive Biotechnologies Provides Strategic Review Update And Announces Preliminary Q1 2024 Revenue Of $41M-$43M Vs $38.21M Est.
ADPT
2 Apr 24
the full value of both MRD and Immune Medicine businesses. I would like to thank Tycho for his financial leadership and significant contributions
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
ADPT
2 Apr 24
would like to thank Tycho for his financial leadership and significant contributions to Adaptive over the past two years, including his leadership
- Prev
- 1
- Next